NF-κB inhibition alleviates carbon tetrachloride-induced liver fibrosis via suppression of activated hepatic stellate cells

Experimental and Therapeutic Medicine

Volumn 8, Issue 1, 2014, Pages 95-99

  Wang, Fei ^a   Liu, Shu Yuan ^a   Du, Tai Ping ^a   Chen, Hao ^a   Li, Zhi Yong ^a   Yan, Jing Wang ^a  

^a XINXIANG MEDICAL UNIVERSITY   (China)

Author keywords

BAY 11 7082; Carbon tetrachloride; Liver fibrosis; Nuclear factor B

Indexed keywords

3 (4 METHYLPHENYLSULFONYL) 2 PROPENENITRILE; ALANINE AMINOTRANSFERASE; ALPHA SMOOTH MUSCLE ACTIN; BETA ACTIN; CARBON TETRACHLORIDE; COLLAGEN TYPE 1; HYDROXYPROLINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL ACTIVATION; CELL CULTURE; CELL VIABILITY; CONTROLLED STUDY; HISTOPATHOLOGY; IN VITRO STUDY; INTRACELLULAR SIGNALING; LIVER FIBROSIS; MALE; MOUSE; MTT ASSAY; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; STELLATE CELL; WESTERN BLOTTING;

EID: 84901364632     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2014.1682     Document Type: Article

References (30)

1. Friedman SL: Mechanisms of hepatic fibrogenesis. Gastroenterology 134: 1655-1669, 2008.
2. Jiao J, Friedman SL and Aloman C: Hepatic fibrosis. Curr Opin Gastroenterol 25: 223-229, 2009.
3. Bataller R and Brenner DA: Liver fibrosis. J Clin Invest 115: 209-218, 2005.
4. Friedman SL: Reversibility of hepatic fibrosis and cirrhosis - is it all hype? Nat Clin Pract Gastroenterol Hepatol 4: 236-237, 2007.
5. Tangkijvanich P and Yee HF Jr: Cirrhosis - can we reverse hepatic fibrosis? Eur J Surg Suppl 587: 100-112, 2002.
6. Povero D, Busletta C, Novo E, et al: Liver fibrosis: a dynamic and potentially reversible process. Histol Histopathol 25: 1075-1091, 2010.
7. Schuppan D and Kim YO: Evolving therapies for liver fibrosis. J Clin Invest 123: 1887-1901, 2013.
8. Gressner AM and Weiskirchen R: Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-beta as major players and therapeutic targets. J Cell Mol Med 10: 76-99, 2006.
9. Gressner AM, Weiskirchen R, Breitkopf K and Dooley S: Roles of TGF-beta in hepatic fibrosis. Front Biosci 7: d793-d807, 2002.
10. Gressner OA and Gressner AM: Connective tissue growth factor: a fibrogenic master switch in fibrotic liver diseases. Liver Int 28: 1065-1079, 2008.
11. Robinson SM and Mann DA: Role of nuclear factor kappaB in liver health and disease. Clin Sci (Lond) 118: 691-705, 2010.
12. Gao Q, Wang XY, Zhou J and Fan J: Cell line misidentification: the case of the Chang liver cell line. Hepatology 54: 1894-1895, 2011.
13. Hao ZM, Cai M, Lv YF, Huang YH and Li HH: Oral administration of recombinant adeno-associated virus-mediated bone morphogenetic protein-7 suppresses CCl(4)-induced hepatic fibrosis in mice. Mol Ther 20: 2043-2051, 2012.
14. Kar S, Ukil A and Das PK: Cystatin cures visceral leishmaniasis by NF-κB-mediated proinflammatory response through co-ordination of TLR/MyD88 signaling with p105-TpI2-ERK pathway. Eur J Immunol 41: 116-127, 2011.
15. Zhao J, Zhang H, Huang Y, et al: Bay11-7082 attenuates murine lupus nephritis via inhibiting NLRP3 inflammasome and NF-κB activation. Int Immunopharmacol 17: 116-122, 2013.
16. Luedde T and Schwabe RF: NF-κB in the liver - linking injury, fibrosis and hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 8: 108-118, 2011.
17. Bonacchi A, Petrai I, Defranco RM, et al: The chemokine CCL21 modulates lymphocyte recruitment and fibrosis in chronic hepatitis C. Gastroenterology 125: 1060-1076, 2003.
18. Seki E, De Minicis S, Osterreicher CH, et al: TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat Med 13: 1324-1332, 2007.
19. Seki E, De Minicis S, Gwak GY, et al: CCR1 and CCR5 promote hepatic fibrosis in mice. J Clin Invest 119: 1858-1870, 2009.
20. Miura K, Kodama Y, Inokuchi S, et al: Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice. Gastroenterology 139: 323-334, 2010.
21. Duffield JS, Forbes SJ, Constandinou CM, et al: Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair. J Clin Invest 115: 56-65, 2005.
22. Son G, Iimuro Y, Seki E, Hirano T, Kaneda Y and Fujimoto J: Selective inactivation of NF-kappaB in the liver using NF-kappaB decoy suppresses CCl4-induced liver injury and fibrosis. Am J Physiol Gastrointest Liver Physiol 293: G631-G639, 2007.
23. Paik YH, Schwabe RF, Bataller R, Russo MP, Jobin C and Brenner DA: Toll-like receptor 4 mediates inflammatory signaling by bacterial lipopolysaccharide in human hepatic stellate cells. Hepatology 37: 1043-1055, 2003.
24. Hellerbrand C, Jobin C, Iimuro Y, Licato L, Sartor RB and Brenner DA: Inhibition of NFkappaB in activated rat hepatic stellate cells by proteasome inhibitors and an IkappaB super-repressor. Hepatology 27: 1285-1295, 1998.
25. Oakley F, Teoh V, Ching-A-Sue G, et al: Angiotensin II activates I kappaB kinase phosphorylation of RelA at Ser 536 to promote myofibroblast survival and liver fibrosis. Gastroenterology 136: 2334-2344, 2009.
26. Schwabe RF, Schnabl B, Kweon YO and Brenner DA: CD40 activates NF-kappa B and c-Jun N-terminal kinase and enhances chemokine secretion on activated human hepatic stellate cells. J Immunol 166: 6812-6819, 2001.
27. Elsharkawy AM, Wright MC, Hay RT, et al: Persistent activation of nuclear factor-kappaB in cultured rat hepatic stellate cells involves the induction of potentially novel Rel-like factors and prolonged changes in the expression of IkappaB family proteins. Hepatology 30: 761-769, 1999.
28. Kluwe J, Pradere JP, Gwak GY, et al: Modulation of hepatic fibrosis by c-Jun-N-terminal kinase inhibition. Gastroenterology 138: 347-359, 2010.
29. Cushing TD, Metz DP, Whittington DA and McGee LR: PI3Kδ and PI3Kγ as targets for autoimmune and inflammatory diseases. J Med Chem 55: 8559-8581, 2012.
30. Jackson LN, Larson SD, Silva SR, et al: PI3K/Akt activation is critical for early hepatic regeneration after partial hepatectomy. Am J Physiol Gastrointest Liver Physiol 294: G1401-G1410, 2008.